Trinity Biosystems raises $7.5M bridge to treat endocrine disorders
Trinity Biosystems, maker of a drug that can treat certain endocrine disorders, has brought in $7.5 million in bridge funding from Amgen Ventures, Life Science Partners, Lilly Ventures, Sanderling Ventures and SR One, according to Dow Jones VentureWire. Based in Menlo Park, Calif., the company has raised about $33.75 million since its first round of financing in 2004.
Life sciences briefing: Tuesday, Feb. 12, 2008
TODAY’S HEADLINES:
Metabolic-disease biotech NGM Biopharma raises $25M (peHUB)
Heart, HIV drug maker Numerate acquires assets of Pharmix (release)
Next-gen sequencer VisiGen promises $1,000 genome by late 2009 (Genome Technology)
CalciMedica raises $5.5M for autoimmune drugs (VentureWire)
Cancer-drug e-marketplace OneOncology raises funds (release)
U.K. biotech Hunter-Fleming acquired by Newron for €8M (release)
Intertek acquires Ireland’s Bioclin Labs, a contract research organization (release)
Metabolic-disease biotech NGM Biopharma raises $25M – South San Francisco-based NGM Biopharmaceuticals (Web site under construction), a biotech developing new drugs for… Continue Reading
Hate novocaine? If so, Novalar has a drug for you
No one likes going to the dentist, and that lingering novocaine numbness usually just makes matters worse. But would you be willing to pay more — possibly a lot more — out-of-pocket for a shot that restores feeling to your face more quickly?
San Diego’s Novalar Pharmaceuticals is betting that you will. The specialty-pharmaceutical firm has been testing a drug it calls NV-101, which it says can cut in half the time it takes people to… Continue Reading
Life sciences briefing: Wednesday, Oct. 31, 2007
Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals
UPDATED: Expanded items on Harmony Info, SymBio Pharma and Merrion Pharma, added Dicerna item.
UPDATE REDUX: Added Syntaxin item.
U.K. biotech Syntaxin raises £16M for pain and nervous-system drugs — Syntaxin, a U.K. biotech focused on drugs that affect cell secretion, raised £16 million ($33.2 million) in a second funding round. The company’s release is here.
Investors in the round included SR One, the venture capital… Continue Reading
Life sciences briefing: Tuesday, Oct. 9, 2007
Featured companies: AngioScore, Forsight Labs, Genoptix, Metastatix, Optherion, QLT
UPDATED: See below.
Artery opener AngioScore pulls in $30M — AngioScore, a Fremont, Calif., maker of balloon catheters used to open up clogged arteries, raised $30 million in a fifth funding round. Investors included Telegraph Hill Partners, Psilos Group Management, QuestMark Partners, L.P., UV Partners, California Technology Ventures and Innomed Ventures.
AngioScore’s balloon catheters, which inflate inside blocked blood vessels to restore blood flow, are designed to overcome problems that sometimes… Continue Reading